Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Kyverna Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Kyverna Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $111.90M, down 18.4% year over year. For fiscal 2025 it was $133.72M, up 18.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.72M | +18.9% |
| FY2024 | Dec 31, 2024 | $112.47M | +125.3% |
| FY2023 | Dec 31, 2023 | $49.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $27.02M | -11.3% |
| Q2 FY2026 | Jun 30, 2026 | $24.79M | -30.8% |
| Q1 FY2026 | Mar 31, 2026 | $30.07M | -19.7% |
| Q4 FY2025 | Dec 31, 2025 | $30.01M | -10.4% |
| Q3 FY2025 | Sep 30, 2025 | $30.46M | +4.3% |
| Q2 FY2025 | Jun 30, 2025 | $35.82M | +31.1% |
| Q1 FY2025 | Mar 31, 2025 | $37.43M | +66.5% |
| Q4 FY2024 | Dec 31, 2024 | $33.48M | +95.1% |
| Q3 FY2024 | Sep 30, 2024 | $29.19M | +114.0% |
| Q2 FY2024 | Jun 30, 2024 | $27.32M | +162.6% |
| Q1 FY2024 | Mar 31, 2024 | $22.48M | +158.0% |
| Q4 FY2023 | Dec 31, 2023 | $17.16M | – |
| Q3 FY2023 | Sep 30, 2023 | $13.64M | – |
| Q2 FY2023 | Jun 30, 2023 | $10.41M | – |
| Q1 FY2023 | Mar 31, 2023 | $8.71M | – |
See a number that looks wrong?